Eli Lilly (LLY -2.47%), like many of its peers in the pharma industry, continues to battle the effects of the patent cliff. Two of its three top-selling products will lose exclusivity this year, but there is one jewel in its crown that investors don't need to worry about. In this video, health care analyst Max Macaluso dives into this drug's clinical use and growth.